{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:04Z","timestamp":1791414124022,"version":"4.3.3"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Gepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains and clinical isolates of\n                    <jats:named-content content-type=\"genus-species\">Mycoplasma pneumoniae<\/jats:named-content>\n                    ,\n                    <jats:named-content content-type=\"genus-species\">Mycoplasma hominis<\/jats:named-content>\n                    ,\n                    <jats:named-content content-type=\"genus-species\">Mycoplasma genitalium<\/jats:named-content>\n                    ,\n                    <jats:named-content content-type=\"genus-species\">Ureaplasma parvum<\/jats:named-content>\n                    , and\n                    <jats:named-content content-type=\"genus-species\">Ureaplasma urealyticum<\/jats:named-content>\n                    in comparison to levofloxacin, moxifloxacin, azithromycin or clindamycin, and tetracycline. Gepotidacin MIC\n                    <jats:sub>90<\/jats:sub>\n                    s (\u03bcg\/ml) were 0.125 (\n                    <jats:named-content content-type=\"genus-species\">M. pneumoniae<\/jats:named-content>\n                    ), 0.032 (\n                    <jats:named-content content-type=\"genus-species\">M. genitalium<\/jats:named-content>\n                    ), 2 (\n                    <jats:named-content content-type=\"genus-species\">M. hominis<\/jats:named-content>\n                    ), and 8 (\n                    <jats:named-content content-type=\"genus-species\">Ureaplasma<\/jats:named-content>\n                    species). Gepotidacin activity was not affected by resistance to fluoroquinolones, tetracyclines, or macrolides in the strains tested. Gepotidacin merits further study for treating infections caused by these organisms.\n                  <\/jats:p>","DOI":"10.1128\/aac.01064-17","type":"journal-article","created":{"date-parts":[[2017,8,7]],"date-time":"2017-08-07T20:40:19Z","timestamp":1502138419000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":17,"title":["<i>In Vitro<\/i>\n                    Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas"],"prefix":"10.1128","volume":"61","author":[{"given":"Ken B.","family":"Waites","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Crabb","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn B.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.697-728.2004"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817381.ch62"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.757-789.2005"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00006-11"},{"key":"e_1_3_2_8_2","first-page":"289","volume-title":"Mollicutes molecular biology and pathogenesis","author":"Waites KB","year":"2014","unstructured":"Waites KB LysynyanskyIBebearCM. 2014. Emerging antimicrobial resistance in mycoplasmas of humans and animals, p 289\u2013322. InBrowningGCittiC (ed), Mollicutes molecular biology and pathogenesis. Caister Academic Press,Norfolk, UK."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2108.150273"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00495-13"},{"key":"e_1_3_2_11_2","volume-title":"Methods for antimicrobial susceptibility testing of human mycoplasmas","author":"Clinical and Laboratory Standards Institute","year":"2011","unstructured":"Clinical and Laboratory Standards Institute. 2011. Methods for antimicrobial susceptibility testing of human mycoplasmas. Approved guideline M43-A. Clinical and Laboratory Standards Institute,Wayne, PA."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02008-16"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1207.051558"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.05.011"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04945-14"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00468-17"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01064-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01064-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:47:10Z","timestamp":1645458430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01064-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1128\/AAC.01064-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01064-17","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727965224.793578632","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"2017-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01064-17"}}